Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-30T16:13:13.111Z Has data issue: false hasContentIssue false
  • English
  • Français

Can individual fatty acids be used as functional biomarkers of dairy fat consumption in relation to cardiometabolic health? A narrative review—CORRIGENDUM

Published online by Cambridge University Press:  19 April 2022

Laury Sellem ,
Kim G. Jackson ,
Laura Paper ,
Ian D. Givens  and
Julie A. Lovegrove
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Corrigendum
Information
British Journal of Nutrition , Volume 128 , Issue 12 , 28 December 2022 , pp. 2510 - 2514
Check for updates
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Nutrition Society

Details of correction: reformatted Table 2 supplied

Existing text:

See Table 2

Table 2. Prospective human studies investigating the associations between circulating levels of odd-chain or trans-fatty acids and incident CVD, CVD mortality or incident type 2 diabetes (T2D)

C15:0, pentadecanoic acid; C17:0, heptadecanoic acid; tPA, trans-palmitoleic acid; M, male; F, female; y, year; T2D, type 2 diabetes; IH, intracerebral haemorrhage; SH, subarachnoid haemorrhage; Apo, apolipoprotein; FA, fatty acids; PA, physical activity; ↑, direct association; ↓, inverse association; ↔, no association.

* HR and OR presented as estimate (95 % confidence interval).

Corrected text should read:

See updated and reformatted Table 2

Table 2. Prospective human studies investigating the associations between circulating levels of odd-chain or trans-fatty acids and incident CVD, CVD mortality or incident type 2 diabetes (T2D)

C15:0, pentadecanoic acid; C17:0, heptadecanoic acid; tPA, trans-palmitoleic acid; M, male; F, female; y, year; T2D, type 2 diabetes; IH, intracerebral haemorrhage; SH, subarachnoid haemorrhage; Apo, apolipoprotein; FA, fatty acids; PA, physical activity; ↑, direct association; ↓, inverse association; ↔, no association.

* HR and OR presented as estimate (95 % confidence interval).

Figure 0

Table 2. Prospective human studies investigating the associations between circulating levels of odd-chain or trans-fatty acids and incident CVD, CVD mortality or incident type 2 diabetes (T2D)

Figure 1

Table 2. Prospective human studies investigating the associations between circulating levels of odd-chain or trans-fatty acids and incident CVD, CVD mortality or incident type 2 diabetes (T2D)